quick eye
Sana Biotechnology Shares (NASDAQ:SANA) recovered 270% post-marketing thanks to positive results from a study involving transplantation of its primary allogeneic islet cell therapy UP421 in a patient with type 1 diabetes without the use of immunosuppression.
The pancreatic cell